Vadim Jucaud, Abraham Shaked, Michele DesMarais, Peter Sayre, Sandy Feng, Josh Levitsky, Matthew J. Everly – 19 September 2018 – The development of human leukocyte antigen (HLA) donor‐specific antibody/antibodies (DSA) is not well described in liver transplant (LT) patients undergoing immunosuppression (IS) withdrawal protocols despite the allograft risk associated with de novo DSA (dnDSA). We analyzed the development of dnDSA in 69 LT patients who received calcineurin inhibitor monotherapy and were enrolled in the ITN030ST study.

Sandeep Satsangi – 19 September 2018

Britt A. Blokker, Monica Maijo, Marta Echeandia, Mikel Galduroz, Angela M. Patterson, Anna Ten, Mark Philo, Rebecca Schungel, Virginia Gutierrez‐de Juan, Emina Halilbasic, Claudia Fuchs, Gwenaelle Le Gall, Malgorzata Milkiewicz, Piotr Milkiewicz, Jesus M. Banales, Simon M. Rushbrook, José M. Mato, Michael Trauner, Michael Müller, María Luz Martínez‐Chantar, Marta Varela‐Rey, Naiara Beraza – 19 September 2018 – Cholestasis comprises aetiologically heterogeneous conditions characterized by accumulation of bile acids in the liver that actively contribute to liver damage.

Jeannette D. Widmer, Andrea Schlegel, Mohamed Ghazaly, Brian Richie Davidson, Charles Imber, Dinesh Sharma, Massimo Malago, Joerg‐Matthias Pollok – 19 September 2018 – The cava‐preserving piggyback (PB) technique requires only partial cava clamping during the anhepatic phase in liver transplantation (LT) and, therefore, maintains venous return and may hemodynamically stabilize the recipient. Hence, it is an ongoing debate whether PB implantation is more protective from acute kidney injury (AKI) after LT when compared with a classic cava replacement (CR) technique.

Charlotte E. Costentin, Yanik J. Bababekov, Andrew X. Zhu, Heidi Yeh – 19 September 2018 – Liver transplantation (LT) is considered the optimal treatment for hepatocellular carcinoma (HCC) because it removes tumor as well as the underlying cirrhotic liver. Because of a global organ shortage, LT for patients with HCC is limited to patients with expected survival comparable to that of nonmalignant indications. Therefore, identifying patients with lower rates of HCC recurrence and higher rates of survival is critical.

Michael L. Volk, Jessica Mellinger, Meena B. Bansal, Ziad F. Gellad, Mark McClellan, Fasiha Kanwal – 18 September 2018 – Healthcare reimbursement is shifting from fee‐for‐service to fee‐for‐value. Cirrhosis, which costs the U.S. healthcare system as much as heart failure, is a prime target for value‐based care. This article describes models in which physician groups or health systems are paid for improving quality and lowering costs for a given population of patients with cirrhosis.

Kristina I. Ringe, Aristeidis Grigoriadis, Emina Halibasic, Frank Wacker, Michael P. Manns, Christoph Schramm, Henrike Lenzen, on behalf of the MRI working group of the IPSCSG – 17 September 2018

15 September 2018

Alice Tung Wan Song, Edson Abdala, Rodrigo Bronze de Martino, Luis Marcelo Sá Malbouisson, Ryan Yukimatsu Tanigawa, Guilherme Marques Andrade, Liliana Ducatti, Andre Mario Doi, João Renato Rebello Pinho, Michele Soares Gomes‐Gouvêa, Fernanda de Mello Malta, Rubens Macedo Arantes, Adriana Coracini Tonacio, Lécio Figueira Pinto, Luciana Bertocco Paiva Haddad, Vinicius Rocha Santos, Rafael Soares Nunes Pinheiro, Lucas Souto Nacif, Flávio Henrique Ferreira Galvão, Venancio Avancini Ferreira Alves, Wellington Andraus, Luiz Augusto Carneiro D’Albuquerque – 15 September 2018

Russell Rosenblatt, Nicholas Russo, Robert S. Brown, Nicole T. Shen, Robert E. Schwartz, Rachel Niec, Shawn Shah, Joseph F. Pisa, Vikas Gupta, Ashley Wu, Zaid H. Tafesh – 15 September 2018